Cargando…
High levels of serum glypican‐1 indicate poor prognosis in pancreatic ductal adenocarcinoma
Carbohydrate antigen 19‐9 (CA19‐9) fails to demonstrate the predictive value for early detection pancreatic ductal adenocarcinoma (PDAC). Glypican‐1 (GPC1+) exosomes may serve as a noninvasive diagnostic tool to detect early stages of PDAC. Therefore, it is necessary to explore the serum GPC1 levels...
Autores principales: | Zhou, Cong‐ya, Dong, Yi‐ping, Sun, Xiao, Sui, Xin, Zhu, Hong, Zhao, Ya‐qin, Zhang, Yuan‐yuan, Mason, Clifford, Zhu, Qing, Han, Su‐xia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246926/ https://www.ncbi.nlm.nih.gov/pubmed/30358133 http://dx.doi.org/10.1002/cam4.1833 |
Ejemplares similares
-
Elevated glypican‐1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma
por: Lu, Haizhen, et al.
Publicado: (2017) -
Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
por: Zhao, Juan, et al.
Publicado: (2022) -
ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma
por: Li, Shuang-Shuang, et al.
Publicado: (2020) -
Low expression of tRF‐Pro‐CGG predicts poor prognosis in pancreatic ductal adenocarcinoma
por: Li, Jun, et al.
Publicado: (2021) -
Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)